Dreismann Heinrich 4
4 · MYRIAD GENETICS INC · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Myriad Genetics (MYGN) Director Heinrich Dreismann Receives 59,701 RSUs
What Happened
Heinrich Dreismann, a director of Myriad Genetics (MYGN), received an award of 59,701 restricted stock units (RSUs) on 2026-06-04. The grant is reported as an award/acquisition (Code A) at $0.00 per share (no cash paid). Each RSU represents a contingent right to one share of common stock subject to vesting.
Key Details
- Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (timely within SEC reporting window).
- Grant: 59,701 RSUs; reported price $0.00; reported total $0.
- Shares owned after transaction: not specified in the provided filing.
- Footnote: RSUs granted under the 2026 Equity Incentive Plan. Each unit vests on the earlier of (a) the first anniversary of the grant or (b) the date of the next annual shareholders meeting.
- Transaction code: A = Award/Grant. No 10b5-1 plan or tax-withholding detail disclosed in this filing.
Context
RSU grants are a standard form of director/executive compensation and do not involve an immediate cash purchase or sale. They typically vest over time (or upon specified events) and therefore are less informative about near-term insider sentiment than open-market purchases or sales. This filing documents the grant mechanics and vesting schedule rather than any immediate change in market exposure.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-04+59,701→ 231,145 total
Footnotes (1)
- [F1]Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.